Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population.

The pharmacogenomics journal - 21 May 2026

Baye Jordan F, Petry Natasha J, Hines Lindsay, Weaver Max, Reinke Michael, Brady Halle, Massmann Amanda, Schultz April

Abstract excerpt

We performed a retrospective cohort study to evaluate risk of antidepressant discontinuation as a function of CYP2C19 and CYP2D6 phenotype. Patients who participated in an elective genomic screening and had a diagnosis of depression or anxiety with a corresponding antidepressant were analyzed. This resulted in 5 808 patients comprising 8 571 antidepressant orders. Of the total antidepressant orders, 51% of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antidepressive Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Citalopram

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP2D6

Share to Depression

Share to Genotype

Share to Pharmacogenomic Testing

Source

Open in PubMed Open full text

Identifiers

PMID: 42168153
DOI: 10.1038/s41397-026-00416-2
PMCID: PMC13193940

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 16 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population.PMID 42168153Read ↗

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocolSemantic proximity Read ↗

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocolSemantic proximity Read ↗

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK BiobankSemantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory studySemantic proximity Read ↗

Exploring the role of drug-metabolising enzymes in antidepressant side effects.Semantic proximity Read ↗

Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.Semantic proximity Read ↗

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.Semantic proximity Read ↗

Association of Atomoxetine Discontinuation Patterns with CYP2D6 Phenotype in Children and Adolescents with Attention Deficit Hyperactivity Disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.